Exagen Inc (XGN)
Exagen Inc. is a healthcare company listed on NASDAQ as common stock under the ticker XGN. The company develops and commercializes diagnostic testing products in the United States under the AVISE brand, with a focus on helping clinicians diagnose, prognose, and monitor complex rheumatic, autoimmune, and autoimmune-related diseases. Its lead product, AVISE CTD, is designed to support differential diagnosis in patients with symptoms that may overlap across connective tissue diseases. Exagen also markets AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE Anti-Histone, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE SLE Monitor, AVISE MTX, and AVISE HCQ. In addition, the company has a research collaboration and license agreement with Allegheny Health Network Research Institute to develop T-Cell biomarkers. Founded in 2002 and headquartered in Vista, California, the company was formerly known as Exagen Diagnostics, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XGN
|
$3.45
|
-29.3% Downside
|
Overvalued
|
$8.57
|
75.8% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-5.8x
|
8.2x
|
1.7x
|
113.1 M
|
123.5 M
|
19.4%
|
57.2%
|
-5.6
|
—
|
70.1%
|
